Visceral leishmaniasis: Advances in treatment

Recent Patents on Anti-Infective Drug Discovery

Volumn 3, Issue 3, 2008, Pages 192-198

  Maltezou, Helen C ^a  

^a Hellenic Center for Disease Control and Prevention   (Greece)

Author keywords

Amphotericin B; Antileishmanial agents; Antimonials; Miltefosine; Resistance; Treatment; Visceral leishmaniasis

Indexed keywords

2 N PROPYLQUINOLINE; 2 NITRILQUINOLINE; ALLICIN; ALOE VERA EXTRACT; AMLODIPINE; AMPHOTERICIN B; AMPHOTERICIN B LIPID COMPLEX; ANTILEISHMANIAL AGENT; AZITHROMYCIN; BUPARVAQUONE; FURAN DERIVATIVE; LACIDIPINE; MEGLUMINE ANTIMONATE; MILTEFOSINE; NICOTINAMIDE; NICOTINIC ACID; NITROVINYLFURAN DERIVATIVE; NYCTANTHES ARBORTRISTIS EXTRACT; PAROMOMYCIN; PLANT EXTRACT; PYRROLE DERIVATIVE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; SERTRALINE; SITAMAQUINE; STIBOGLUCONATE SODIUM; UNCLASSIFIED DRUG;

AMINOTRANSFERASE BLOOD LEVEL; ANTIPROTOZOAL ACTIVITY; ARTICLE; CD4+ T LYMPHOCYTE; CHILL; CLINICAL TRIAL; CREATININE BLOOD LEVEL; CYTOKINE PRODUCTION; DRUG CHOICE; DRUG COST; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG FEVER; DRUG STRUCTURE; DRUG TREATMENT FAILURE; ENDEMIC DISEASE; EPIDEMIC; GASTROINTESTINAL TOXICITY; HALF LIFE TIME; HEART ARRHYTHMIA; HOSPITALIZATION COST; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPOKALEMIA; IMMUNE RESPONSE; INFECTION RATE; INJECTION SITE PAIN; LEISHMANIA DONOVANI; MIXED INFECTION; MONOTHERAPY; NEPHROTOXICITY; NONHUMAN; OTOTOXICITY; PANCREATITIS; PARASITE TRANSMISSION; PARASITE VECTOR; PATHOGENESIS; PATIENT COMPLIANCE; PNEUMONIA; PRIORITY JOURNAL; PSYCHODIDAE; PUBLIC HEALTH PROBLEM; RELAPSE; SECONDARY PREVENTION; SIDE EFFECT; SKIN LEISHMANIASIS; SYSTEMIC DISEASE; VISCERAL LEISHMANIASIS;

EID: 58149133829     PISSN: 1574891X     EISSN: None     Source Type: Journal    
DOI: 10.2174/157489108786242341     Document Type: Article

References (74)

1. Murray HW, Berman JD, Davies CR, Saravia NG. Advances in leishmaniasis. Lancet 2005; 366: 1567-1577.
2. Kafetzis DA, Maltezou HC. Visceral leishmaniasis in pediatrics. Curr Opin Infect Dis 2002; 15: 289-294.
3. Chappuis F, Sundar S, Hailu A, et al. Visceral leishmaniasis: What are the needs for diagnosis, treatment and control? Nat Rev Microbiol 2007; 5: S7-16.
4. Maltezou CH, Siafas C, Mavrikou M, et al. Visceral leishmaniasis during childhood in Southern Greece. Clin Infect Dis 2000; 31: 1139-1143.
5. Raguenaud ME, Jansson A, Vanlerberghe V, et al. Epidemiology and clinical features of patients with visceral leishmaniasis treated by MSF clinic in Bakool region, Somalia, 2004-2006. PloS Negl Trop Dis 2007; 1:e85.
6. Minodier P, Piarroux R, Garnier JM, Unal D, Perrimond H, Dumon H. Pediatric visceral leishmaniasis in southern France. Pediatr Infect Dis J 1998; 17: 701-704.
7. Singh UK, Prasad R Mishra OP, Jayswal BP. Miltefosine in children with visceral leishmaniasis: A prospective, multicentric, cross-sectional study. Indian J Pediatr 2006; 73: 1077-1080.
8. Kolaczinski JH, Hope A, Antonio J, Rumunu J, Richer M, Seaman J. Kala-azar epidemiology and control, southern Sudan. Emerg Infect Dis 2008; 14: 664-666.
9. World Health Organization. Global Plan to combat neglected tropical diseases 2008-2015, last accessed: August 17, 2008, at: http://whqlibdoc.who.int/hq/2007/WHO_CDS_NTD_2007.3_eng.pdf.
10. Croft SL, Sundar S, Fairlamb AH. Drug resistance in leishmaniasis. Clin Microbiol Rev 2006; 19: 111-126.
11. Salomon OD, Sinagra A, Nevot MC, et al. First visceral leishmaniasis focus in Argentina. Mem Inst Oswaldo Cruz, Rio de Janeiro 2008; 103: 109-11.
12. Santos OD, Coutinho CER, Madeira MF, et al. Leishmaniasis treatment-a challenge that remains: a review. Parasitol Res 2008; 103(1): 1-10.
13. Antinori S, Cascio A, Parravicini C, Bianchi R, Corbeillino M. Leishmaniasis among organ transplant recipients. Lancet Infect Dis 2008; 8: 191-199.
14. Murray HW, Hariprashad J, Fichtl RE. Models of relapse of experimental visceral leishmaniasis. J Infect Dis 1996; 173: 1041-1043.
15. Spellberg B, Edwards JE Jr. Type 1/type 2 immunity in infectious diseases. Clin Infect Dis 2001; 32: 76-102.
16. McFarlane E, Perez C, Charmony M, et al. Neutrophils contribute to development of a protective immune response during onset of infection with Leishamania donovani. Infect Immun 2008; 76: 532-541.
17. Jeronimo SM, Holst AK, Jamieson SE, et al. Genes at human chromosome 5q31.1 regulate delayed-type hypersensitivity responses associated with Leishmania chagasi infection. Genes Immun 2007; 8: 539-551.
18. Jeronimo SMB, Duggal P, Ettinger NA, et al. Genetic predisposition to self-curing infection with the protozoan Leishamania chagasi: a genome wide scan. J Infect Dis 2007; 196: 1261-1269.
19. Dujardin JC, Campino L, Capavate C, et al. Spread of vector-borne diseases and neglect of leishmaniasis, Europe. Emerg Infect Dis 2008; 14: 1013-1018.
20. Riera C, Fisa R, Lopez-Chejade P, et al. Asymptomatic infection by Leishmania infantum in blood donors from the Balearic Islands (Spain). Transfusion 2008; 48: 1383-1389.
21. Oliveira CM, Oliveira ML, Andrade SC, et al. Visceral leishmaniasis in renal transplant recipients: Clinical aspects, diagnostic problems, and response to treatment. Transplant Proc 2008; 40: 7555-7560.
22. Cruz I, Morales MA, Noguer I, Rodriguez A, Alvar J. Leishmania in discarded syringes from intravenous drug users. Lancet 2002; 359: 1124-1125.
23. Cortes S, Odete Afonso M, Alves-Pires C, Campino L. Stray dogs and leishamaniasis in urban areas, Portugal. Emerg Infect Dis 2007; 13: 1431-1432.
24. Tselentis Y, Gikas A, Chaniotis B. Kala-azar in Athens basin. Lancet 1994; 343: 1635.
25. Olliaro PL, Guerin PJ, Gerstl S, Aga-Haaskjold A, Rottingen JA, Shyan S. Treatment options for visceral leishmaniassis: A systematic review of clinical studies done in India, 1980-2004. Lancet Infect Dis 2005; 5: 763-774.
26. Malik ANJ, John L, Bryceson ADM, Lockwood DNJ. Changing pattern of visceral leishmaniasis, United Kingdom, 1985-2004. Emerg Infect Dis 2006; 12: 1257-1259.
27. Joshi A, Narain JP, Prasittisuk C, et al. Can visceral leishmaniasis be eliminated from Asia? J Vector Borne Dis 2008; 45: 105-111.
28. Casimiro E, Calheiros J, Santos Duarte F, Kovats S. National assessment of human health effects of climate change in Portugal: Approach and key findings. Environ Health Perspect 2006; 114: 1950-1956.
29. Maroli M, Rossi L, Baldelli R, et al. The northward spread of leishmaniasis in Italy: Evidence from retrospective and ongoing studies on the canine reservoir and phlebotomine vectors. Trop Med Int Health 2008; 13: 256-264.
30. Cardenas R, Sandoval CM, Rodriguez-Morales AJ, Franco-Paredes C. Impact of climate variability in the occurrence of leishmaniasis in Northeastern Colombia. Am J Trop Med Hyg 2006; 75: 273-277.
31. Sutherst RW. Global change and human vulnerability to vectorborne diseases. Clin Microbiol Rev 2004; 17: 136-173.
32. Sundar S, Thakur BB, Tandon AK, et al. Clinicoepidemoilogical study of drug resistance in Indian kala- azar. BMJ 1994: 308: 307.
33. Ter Horst R, Collin SM, Ritmeijer K, Bogale A, Davidson RN. Concordant HIV infection and visceral leishmaniasis in Ethiopia: The influence of antiretroviral treatment and other factors on outcome. Clin Infect Dis 2008; 46: 1702-1709.
34. Russo R, Nigro L, Panarello G, Montineri A. Clinical survey of Leishmania/HIV co-infection in Catania, Italy: The impact of highly active antiretroviral therapy (HAART). Ann Trop Med Parasitol 2003; 97 (Suppl 1): S149-155.
35. Alvar J, Aparicio P, Aseffa A, et al. The relationship between leishmaniasis and AIDS: the second 10 years. Clin Microbiol Rev 2008; 21: 334-59.
36. Rabello A, Orsini M, Disch J. Leishmania/HIV co-infection in Brazil: an appraisal. Ann Trop Med Parasitol 2003; 97 (Suppl 1): S17-28.
37. Sundar S, Chatterjee M. Visceral leishmaniasis-current therapeutic modalities. Indian J Med Res 2006; 123: 345-352.
38. Jha TK. Drug unresponsiveness and combination therapy for kalaazar. Indian J Med Res 2006; 123: 389-398.
39. Ritmeijer K, Dejenie A, Assefa Y, et al. A comparison of miltefosine and sodium stibogluconate for treatment of visceral leishmaniasis in an Ethiopian population with high prevalence of HIV infection. Clin Infect Dis 2006: 43: 357-364.
40. Sundar S, Chakravarty J, Rai VK, et al. Amphotericin B treatment for Indian visceral leishmaniasis: response to 15 daily versus alternate-day infusions. Clin Infect Dis 2007; 45: 556-561.
41. Manandhar KD, Yadav TP, Prajapati VK, et al. Antileishmanial activity of nano-amphotericin B deoxycholate. J Antimicrob Chemother 2008; 62: 376-380.
42. Ordonez-Gutierrez L, Espada-Fernandez R, Dea-Ayuela MA, Torrado JJ, Bolas-Fernandez F, Alunda JM. in vitro Effect of new formulations of amphotericin B on amastigote and promastigote forms of Leismania infantum. Int J Antimicrob Agents 2007; 30: 325-329.
43. Torrado JJ, Espada R, Ballesteros MP, Torrado-Santiago S. Amphotericin B formulations and drug targeting. J Pharm Sci 2008; 97: 2405-2425.
44. Gupta S, Dude A, Vyas SP. Antileishmanial efficacy of amphotericin-B bearing emulsomes against experimental visceral leishmaniasis. J Drug Target 2007; 15: 437-444.
45. Petit C, Yardley V, Gaboriau F, Bolard J, Croft SL. Activity of heat-induced reformulation of amphotericin B deoxycholate (fungizone) against Leishmania donovani. Antimicrob Agents Chemother 1999; 43: 390-392.
46. Bhattacharya SK, Sinha PK, Sudar S, et al. Phase 4 trial of miltefosine for the treatment of Indian visceral leishamaniasis. J Infect Dis 2007; 196: 591-598.
47. Croft SL, Seifert K, Yardley V. Current scenario of drug development for leishmaniasis. Indian J Med Res 2006; 123: 399-410.
48. Seifert K, Perez-Victoria FJ, Stettler M, et al. Inactivation of the miltefosine transporter, LdMT, causes miltefosine resistance that is conferred to the amastigote stage of Leishmania donovani and persists in vivo. Int J Antimicrob Agents 2007; 30: 229-235.
49. Seifert K, Matu S, Javier Perz-Victoria F, Castany S, Gamarro F, Croft SL. Characterization of Leishmania donovani promastigotes resistant to hexadecylphospocholine (miltefosine). Int J Antimicrob Agents 2003; 22: 380-387.
50. Sundar S, Jha TK, Thakur CP, Sinha PK, Bhattacharya SK. Injectable paromomycin for visceral leishmaniasis in India. N Engl J Med 2007; 356: 2571-2581.
51. Melaku Y, Collin SM, Gatluak F, Ritmeijer K, Davinson RN. Treatment of kala-azar in southern Sudan using a 17-day regimen of sodium sribogluconate with paromomycin: A retrospective comparison with 30-day sodium stibogluconate monotherapy. Am J Trop Med Hyg 2007; 77: 89-94.
52. Seifert K, Croft SL. in vitro and in vivo Interactions between miltefosine and other antileishmanial drugs. Antimicrob Agents Chemother 2006; 50: 73-79.
53. Laguna F. Treatment of leishmaniasis in HIV-positive patients. Ann Trop Med Parasitol 2003; 97 (Suppl 1): S135-142.
54. Di Giorgio C, Faraut-Gambarelli F, Imbert P, Minodier P, Gasquest M, Dumon H. Flow cytometric assessment of amphotericin-B susceptibility in Leishmania infantum isolates from patients with visceral leishmaniasis. J Antimicrob Chemother 1999; 44: 71-76.
55. Bourgeois N, Lachaud L, Reynes J, Rouanet I, Mahamat A, Bastien P. Long-term monitoring of visceral leishmaniasis in patients with AIDS: Relapse risk factors, value of polymerase chain reaction, and potential impact on secondary prophylaxis. J Acquir Immune Defic Syndr 2008; 48: 13-19.
56. Molina I, Falco V, Crespo M, et al. Efficacy of liposomal amphotericin B for secondary prophylaxis of visceral leishmaniasis in HIV-infected patients. J Antimicrob Chemother 2007; 60:837-842.
57. De Oliveira-Silva F, de Morais-Teixeira E, Rabello A. Antileishmanial activity of azithromycin against Leishmania (Leishmania) amozonensis, Leishmania (Viannia) braziliensis, and Leishmania (Leishmania) chagasi. Am J Trop Med Hyg 2008; 78: 745-749.
58. Palit P, Paira P, Hazra A, et al. Phase transfer catalyzed synthesis of bis-quinolines: Antileishmanial activity in experimental visceral leishmaniasis and in vitro antibacterial evaluation. Eur J Med Chem 2008 (in press).
59. Nakayama H, Loiseau PM, Bories C, et al. Efficacy of orally administered 2-substituted quinolines in experimental murine cutaneous and visceral leishmaniases. Antimicrob Agents Chemother 2005; 49: 4950-4956.
60. Nakayama H, Desrivot J, Bories C, et al. in vitro and in vivo Antileishmanial efficacy of a new nitrilquinoline against Leishmania donovani. Biomed Pharmacother 2007; 61: 186-188.
61. Garnier T, Mantyla A, Jarvinen T, Lawrence J, Brown M, Croft S. in vivo Studies on the antileishamanial activity of buparvaquone and its prodrugs. J Antimicrob Chemother 2007; 60: 802-810.
62. Castapedo, C.N.R., Sifontes, R.S., Monzote, F.L., Lopez, H.Y., Montalvo, A.A.M., Infante, B.J.F., Olazábal, M.E.E.: EP1941877A1 (2006).
63. Palit P, Ali N. Oral therapy with sertraline, a selective serotonin reuptake inhibitor, shows activity against Leishmania donovani. J Antimicrob Chemother 2008; 61: 1120-1124.
64. Palit P, Ali N. Oral therapy with amlodipine and lacidipine, 1,4-dihydropyridine derivatives showing activity against experimental visceral leishmaniasis. Antimicrob Agents Chemother 2008; 52: 374-377.
65. Quaissi, A., Sereno, D., Vergnes, B.: US20080039430A1 (2008).
66. Searle, A.D.: WO08043726A1 (2008).
67. Cordeiro da Silva, A., Pinto da Costa, T.J.A., Kong, T.L.P.: WO08007262A2 (2008).
68. Fischer, G., Schiene-Fischer, C., Daum, S., Kullertz, G., Braun, M., Feaux de Lacroix, B.: WO08019823A3 (2008).
69. Beverley, S.M., Zhang, K.: US20080119483A1 (2008).
70. Chakraborty D, Basu J.M, Sen P, Sundar S, Roy S. Human placental exctract offers protection against experimental visceral leishmaniasis: A pilot study for a phase-I clinical trial. Ann Trop Med Parasitol 2008; 102: 21-38.
71. Dutta A, Sarkaw D, Gurib-Fakim A, Mandal C, Chatterjee M. in vitro and in vivo Activity of Aloe vera leaf exudates in experimental visceral leishmaniasis. Parasitol Res 2008; 102: 1235-1242.
72. Singh N, Kumar R, Gupta S, Dube A, Lakshmi V. Antileishmanial activity in vitro and in vivo of constituents of sea cucumber Actinopyga lecanora. Parasitol Res 2008; 103: 351-354.
73. Chattopadhyat, S., Achari, B., Poddar, A., Kumar, A.: WO07042902A2 (2007).
74. Bennett, N.J., Josling, P.D.: US20070036875A1 (2007).